GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
Betsy Goodfellow | March 7, 2024 | News story | Research and Development | Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) as a second line and later treatment for relapsed or refractory multiple myeloma.
The trial compared the drug to a standard of care, bortezomib plus PomDex, and met its primary endpoint of progression-free survival (PFS) at a pre-specified interim analysis. The combination was shown to significantly extend the time to disease progression or death compared to standard of care, with the trial demonstrating a positive overall survival (OS) trend in favour of the Blenrep combination.
The trial will continue to assess OS, however the safety and tolerability of the drug regimen was broadly consistent with known safety profiles of the drugs.
Hesham Abdullah, senior vice president and global head of Oncology Research and Development at GSK, commented: “The results seen in both DREAMM-7 and DREAMM-8 provide strong clinical evidence of the robust efficacy shown with belantamab mafodotin in use with standard of care combinations. We now look forward to discussing this data with regulators. If approved, we believe these combinations have the potential to redefine the treatment of relapsed or refractory multiple myeloma and advance the standard of care. This is exciting news for patients given the high unmet medical need for both efficacious and easily administered therapies with differing mechanisms of action.”
Betsy Goodfellow
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
